Start by deciding what you are procuring—not by asking who has the lowest semaglutide or tirzepatide price. Build separate workstreams for purchasing clinic stock, appointing dispensing pharmacies and helping patients use manufacturer-linked access programmes. The latter programmes publish patient prescription workflows; they should not be treated as evidence that a clinic can purchase wholesale inventory. See the LillyDirect provider instructions and NovoCare provider delivery instructions.
This playbook recommends completing five decisions in order:
- Control: Which expenditures and operational decisions does the clinic actually control?
- Eligibility: Is the exact product, facility, destination and intended arrangement supportable?
- Capability: Can the proposed partners execute the required patient journey?
- Economics: What will the clinic, patient and payer each spend under matched assumptions?
- Continuity: What happens when a prescription, delivery, supplier or access programme fails?
Do not let price compensate for an unresolved legal or quality gate. FDA recommends using compounded drugs only when an FDA-approved drug cannot meet the patient's medical needs; compounded products do not undergo the same FDA premarket review. FDA: concerns with unapproved GLP-1 drugs. (fda.gov)
What you should finish with: a signed decision brief, product-and-state eligibility matrix, independently checked supplier evidence register, comparable cost workbook, negotiated responsibilities, tested prescribing workflow and an executable transition plan.
How should you interpret this guide?
Regulatory and programme statements below are sourced facts. Timelines, staffing allocations, document templates, scoring weights and example budgets are proposed planning tools, not measured industry averages. Supplier capabilities remain unverified until tested for your organisation.
This is procurement decision support, not a legal opinion, prescribing protocol or instruction to compound medicines. Qualified US counsel should review the proposed arrangement; clinical leaders retain treatment decisions.
Answers stay in this session unless you choose to save. No account needed.
Sources cited on this page
- lilly.com · Source 1 ↗https://www.lilly.com/lillydirect/hcp/
- novocare.com · Source 2 ↗https://www.novocare.com/hcp/delivery.html
- fda.gov · Source 3 ↗https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
- fda.gov · Source 4 ↗https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss?os=av&utm_source=openai